Evidence map›Paper›PMID 26261602›Full record

ArticleInternational journal of clinical and experimental pathology2015

The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer.

Wang-Yang Chen, Xiao-Juan Zhao, Zhi-Fu Yu, Fu-Lan Hu, Yu-Peng Liu, Bin-Bin Cui, Xin-Shu Dong, Ya-Shuang Zhao

Open access · greenAbstract readEvaluation Study
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 7 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 7 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer.Frontiers in cell and developmental biology · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wang-Yang ChenDepartment of Epidemiology, Public Health College, Harbin Medical University Harbin, Heilongjiang 150081, P. R. China.
Xiao-Juan ZhaoDepartment of Epidemiology, Public Health College, Harbin Medical University Harbin, Heilongjiang 150081, P. R. China.
Zhi-Fu YuDepartment of Epidemiology, Public Health College, Harbin Medical University Harbin, Heilongjiang 150081, P. R. China.
Fu-Lan HuDepartment of Epidemiology, Public Health College, Harbin Medical University Harbin, Heilongjiang 150081, P. R. China.
Yu-Peng LiuDepartment of Epidemiology, Public Health College, Harbin Medical University Harbin, Heilongjiang 150081, P. R. China.
Bin-Bin CuiDepartment of Abdominal Surgery, The Tumor Hospital of Harbin Medical University Harbin, Heilongjiang Province, P. R. China.
Xin-Shu DongDepartment of Tumor Surgery, The Forth Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang Province, P. R. China.
Ya-Shuang ZhaoDepartment of Epidemiology, Public Health College, Harbin Medical University Harbin, Heilongjiang 150081, P. R. China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating microRNAs (miRNAs) were recognized to be potential non-invasive biomarkers for colorectal cancer (CRC) detection and prediction. Meanwhile, the association of the expression of plasma miRNAs with the risk of CRC patients has rarely been analyzed. Therefore, we conducted this study to evaluate the value of plasma miRNAs for CRC diagnosis and risk estimation. Fasting blood samples from 100 CRC patients and 79 cancer-free controls were collected. Plasma miR-106a, miR-20a, miR-27b, miR-92a and miR-29a levels were detected by RT-qPCR. Sensitivity and specificity were employed to evaluate the diagnostic value of miRNAs for CRC. Univariate and multivariate logistic regression were employed to analyze the association between miRNAs expression and CRC risk. As results, miR-106a and miR-20a were elevated in the patients with CRC. The sensitivity of miR-106a was 74.00% and the specificity was 44.40%, while the cutoff value was 2.03. As for miR-20a, the sensitivity was 46.00% and specificity was 73.42% when employed 2.44 as cutoff value. High expression of plasma miR-106a increased CRC risk by 1.80 -fold. Plasma miR-106a and miR-20a may as noninvasive biomarkers for detecting the CRC. High expression of miR-106a associated with CRC risk.

Indexed as

AdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorCase-Control StudiesChi-Square DistributionColorectal NeoplasmsFemaleGenetic TestingHumansLogistic ModelsMaleMicroRNAsMiddle AgedMultivariate AnalysisBiomarkers, TumorMicroRNAscolorectal cancerdiagnosismicroRNAplasmarisk factor

Identifiers

PMID26261602
PMCPMC4525936
OpenAlexW2413737165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.